Construction method of idiopathic pulmonary fibrosis plasma cell characteristic gene prognosis model
The invention provides an idiopathic pulmonary fibrosis plasma cell characteristic gene prognosis model construction method, which comprises the following steps: carrying out single cell transcriptome data analysis, carrying out tissue level transcriptome data differential expression gene analysis, carrying out immune cell infiltration analysis, and carrying out weighted gene co-expression network analysis. The method comprises the following steps: screening plasma cell related candidate genes, scoring the plasma cell related candidate genes, performing functional pathway enrichment analysis on the plasma cell related candidate genes, performing construction and internal evaluation of an IPF prognosis model, and performing external evaluation of the IPF prognosis model. According to the construction method of the idiopathic pulmonary fibrosis plasma cell characteristic gene prognosis model, the prognosis model capable of distinguishing patients in a low-risk group from patients in a high-risk group is established, and the construction method can be applied to auxiliary judgment of prognosis conditions of patients with idiopathic pulmonary fibrosis and is beneficial to research and development of novel drug targets and establishment of novel monitoring schemes..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Europäisches Patentamt - (2024) vom: 02. Feb. Zur Gesamtaufnahme - year:2024 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
LU WENJU [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Sonstige Themen: |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2024-02-02, Last update posted on www.tib.eu: 2024-04-15, Last updated: 2024-04-19 |
|---|
| Patentnummer: |
CN117497062 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA002738171 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA002738171 | ||
| 003 | DE-627 | ||
| 005 | 20240419121453.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240329s2024 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA002738171 | ||
| 035 | |a (EPA)CN117497062 | ||
| 035 | |a (EPA)89679771 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a LU WENJU |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Construction method of idiopathic pulmonary fibrosis plasma cell characteristic gene prognosis model |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2024-02-02, Last update posted on www.tib.eu: 2024-04-15, Last updated: 2024-04-19 | ||
| 520 | |a The invention provides an idiopathic pulmonary fibrosis plasma cell characteristic gene prognosis model construction method, which comprises the following steps: carrying out single cell transcriptome data analysis, carrying out tissue level transcriptome data differential expression gene analysis, carrying out immune cell infiltration analysis, and carrying out weighted gene co-expression network analysis. The method comprises the following steps: screening plasma cell related candidate genes, scoring the plasma cell related candidate genes, performing functional pathway enrichment analysis on the plasma cell related candidate genes, performing construction and internal evaluation of an IPF prognosis model, and performing external evaluation of the IPF prognosis model. According to the construction method of the idiopathic pulmonary fibrosis plasma cell characteristic gene prognosis model, the prognosis model capable of distinguishing patients in a low-risk group from patients in a high-risk group is established, and the construction method can be applied to auxiliary judgment of prognosis conditions of patients with idiopathic pulmonary fibrosis and is beneficial to research and development of novel drug targets and establishment of novel monitoring schemes. | ||
| 650 | 4 | |a G16B: Bioinformatics, i.e. information and communication technology [ict] specially adapted for genetic or protein-related data processing in computational molecular biology | |
| 650 | 4 | |a G16H: Healthcare informatics, i.e. information and communication technology [ict] specially adapted for the handling or processing of medical or healthcare data | |
| 650 | 4 | |a rest | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a LIN FANJIE |e verfasserin |4 aut | |
| 700 | 0 | |a ZHANG ZILI |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2024) vom: 02. Feb. |
| 773 | 1 | 8 | |g year:2024 |g day:02 |g month:02 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/89679771/publication/CN117497062A1?q=CN117497062 |x 0 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 02 |c 02 | ||